Whittier Trust Co. of Nevada Inc. Has $20.50 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Whittier Trust Co. of Nevada Inc. raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,189 shares of the medical research company's stock after purchasing an additional 602 shares during the quarter. Whittier Trust Co. of Nevada Inc.'s holdings in Thermo Fisher Scientific were worth $20,495,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Whittier Trust Co. increased its holdings in Thermo Fisher Scientific by 1.5% during the 1st quarter. Whittier Trust Co. now owns 88,940 shares of the medical research company's stock worth $44,255,000 after purchasing an additional 1,351 shares during the last quarter. ESG Planning DBA Harper Investing boosted its position in Thermo Fisher Scientific by 40.0% during the 1st quarter. ESG Planning DBA Harper Investing now owns 1,219 shares of the medical research company's stock valued at $607,000 after purchasing an additional 348 shares during the period. Prevail Innovative Wealth Advisors LLC boosted its position in Thermo Fisher Scientific by 1,721.3% during the 1st quarter. Prevail Innovative Wealth Advisors LLC now owns 7,340 shares of the medical research company's stock valued at $3,652,000 after purchasing an additional 6,937 shares during the period. Cornercap Investment Counsel Inc. acquired a new position in Thermo Fisher Scientific during the 1st quarter worth $1,499,000. Finally, Graybill Wealth Management LTD. acquired a new position in Thermo Fisher Scientific during the 1st quarter worth $6,460,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on TMO shares. Barclays cut their price objective on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a report on Tuesday, June 24th. Stifel Nicolaus dropped their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Evercore ISI dropped their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Finally, Royal Bank Of Canada decreased their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average target price of $600.30.

Thermo Fisher Scientific Trading Down 0.4%

Shares of NYSE:TMO traded down $1.58 during midday trading on Wednesday, hitting $416.42. The company had a trading volume of 2,762,254 shares, compared to its average volume of 2,012,529. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The stock has a market cap of $157.19 billion, a price-to-earnings ratio of 24.42, a PEG ratio of 2.22 and a beta of 0.77. The firm has a fifty day simple moving average of $409.84 and a 200 day simple moving average of $474.37.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period in the previous year, the company posted $5.11 earnings per share. The company's revenue for the quarter was up .2% on a year-over-year basis. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.